Changing market dynamics over the past ten years has not held back the robust Skin Substitute/CTP market.

As SmartTRAK celebrates its 10-year anniversary covering AWC and the Biologics area, we look back at the market drivers, products and players to see how the US Skin Substitute market has changed over the last decade. We also look ahead to see what is in store for the Skin Substitute market, which is projected to reach $1.64B in 2025E.

The following is a preview of our Wound Biologics market retrospective. The full article, available on SmartTRAK, features our industry experts discussing and analyzing these changes and trends in detail.

A return to positive growth for the quarter, but gains lag behind pre-COVID-19 levels.

The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Among the many topics covered in detail in our comprehensive Q121 US Infection Prevention - Vascular Access (VA) Adjunct Products Market Recap* are:

Advanced Wound Care begins to stabilize as in-person visits increase and elective procedures rebound.

For Q121, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was up +6.2%, boosted by a strong performance in Biologics, with 3M maintaining the number one position in the AWC space.

Among the many topics covered in detail in our comprehensive Q121 AWC Market Recap* are:

Procedures using surgical matrices continued their recovery, with breast matrices benefiting more from comparison to the early stages of the pandemic that began last year.

Procedures using surgical matrices resumed their return to pre-COVID levels. The US Surgical Matrices market returned to growth according to BioMedGPS’ SmartTRAK Financial Dashboard. AbbVie continued to lead the Surgical Matrices market while Becton Dickinson (BD), although still leading the US Hernia Matrices market, continued to slide as the hernia market lagged the recovery in breast matrices.

Among the many topics covered in detail in our comprehensive Q121 US Surgical Matrices Market Recap* are:

The US market for Hemostats and Sealants resumed its growth in Q121 as procedures climbed back towards normal.

While surgical procedures have not fully regained their pre-COVID levels, the US Hemostats and Sealants market grew in Q121 according to SmartTRAK Financial Dashboard. However, it continued to be a tale of two recoveries. CryoLife* and especially JNJ/Ethicon* posted solid gains for the quarter. However, as elective procedures continue to be behind pre-COVID levels, other manufacturers lagged by comparison.

The Symposium on Advanced Wound Care, SAWC, the official meeting of the Wound Healing Society, was held virtually May 10-14 and SmartTRAK attended.

Following is a sampling of some of the takeaways from the meeting that were gathered and curated by our expert analysts and sent out to subscribers in our Daily Updates.

A year of turbulence as COVID-19 affects the WW Advanced Wound Care market at different times and in a variety of ways throughout the year.

For FY20, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was down -1.9% YoY. Q420 grew +1.0%, reflecting the gradual recovery in the market.

Among the many topics covered in the comprehensive Q420/FY20 Advanced Wound Care Market Recap* are:

Anticipated growth for Q4 was weakened by a resurgence of COVID-19 and was not enough to sustain growth with FY20 ending at -3.3% YoY decline.

For FY20, according SmartTRAK Financial Dashboard, the US Infection Prevention - Vascular Access (VA) Adjunct Products market was down -3.3% YoY, while Q420 revenue was up  +1.2% YoY.

The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Among the many topics covered in the comprehensive Q420/FY20 Infection Prevention: US Vascular Access Adjunct Market* are:

Ragna Ouwerkerk, PR Manager at Mediq, discusses the Company and its recent acquisitions in an interview with SmartTRAK.

Mergers and acquisitions have become an attractive business strategy for companies in the wound care space considering to expand into new markets or territories, reach a competitive edge or obtain new technologies. One company looking to strengthen its leadership position in the European wound care market through acquisitions is  Mediq.

Mediq is a Dutch healthcare company founded in 1899 by ninety-one pharmacists as a type of buying group to check the quality of raw materials and medicines. In 2021, Mediq provides pharmaceuticals and medical devices to patients and healthcare facilities globally. Recently, the Company decided to take a major step forward and has had a flurry of acquisitions in the last few months of which some strengthened the presence of the company in some European countries and another helped to enter the UK market.

SmartTRAK: The Company has recently acquired Medirum AB in Sweden, Puls AS in Norway, H&R Healthcare Ltd in the UK, GD Medical AG in Switzerland and Replant 4 Care in Hungary. Mediq also intends to acquire Eurocept Homecare and Da Vinci Kliniek in the Netherlands. What was your thinking behind those acquisitions?

The recovery in breast and hernia procedure stalled in Q420, with revenue dropping -9.2% YoY, according to BioMedGPS’ SmartTRAK Financial Dashboard. AbbVie* maintained its lead despite the effects of the pandemic, off -8.4% YoY, as its breast matrices continued to lag in the overall recovery. Becton Dickinson* (BD) slid –1.2% YoY as hernia procedures bounced back to normal levels a little faster ...

Among the many topics covered in the comprehensive Q420/FY20 US Surgical Matrices Market Recap* are: